200 related articles for article (PubMed ID: 19328496)
1. Different tissue distribution of paclitaxel with intravenous and intraperitoneal administration.
Soma D; Kitayama J; Ishigami H; Kaisaki S; Nagawa H
J Surg Res; 2009 Jul; 155(1):142-6. PubMed ID: 19328496
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics and tissue distribution of intraperitoneal paclitaxel with different carrier solutions.
Mohamed F; Marchettini P; Stuart OA; Sugarbaker PH
Cancer Chemother Pharmacol; 2003 Nov; 52(5):405-10. PubMed ID: 12879282
[TBL] [Abstract][Full Text] [Related]
3. Docetaxel: pharmacokinetics and tissue levels after intraperitoneal and intravenous administration in a rat model.
Marchettini P; Stuart OA; Mohamed F; Yoo D; Sugarbaker PH
Cancer Chemother Pharmacol; 2002 Jun; 49(6):499-503. PubMed ID: 12107555
[TBL] [Abstract][Full Text] [Related]
4. Intra-peritoneal administration of paclitaxel with non-animal stabilized hyaluronic acid as a vehicle--a new strategy against peritoneal dissemination of gastric cancer.
Yamada J; Kitayama J; Tsuno NH; Yamashita H; Miyato H; Soma D; Otani K; Kamei T; Ishigami H; Hidemura A; Kaisaki S; Takahashi K; Nagawa H
Cancer Lett; 2008 Dec; 272(2):307-15. PubMed ID: 18768251
[TBL] [Abstract][Full Text] [Related]
5. Effect of interleukin-2 pretreatment on paclitaxel absorption and tissue disposition after oral and intravenous administration in mice.
Hosten B; Abbara C; Petit B; Dauvin A; Bourasset F; Farinotti R; Gonin P; Bonhomme-Faivre L
Drug Metab Dispos; 2008 Aug; 36(8):1729-35. PubMed ID: 18508881
[TBL] [Abstract][Full Text] [Related]
6. Plasma and tissue disposition of paclitaxel (taxol) after intraperitoneal administration in mice.
Innocenti F; Danesi R; Di Paolo A; Agen C; Nardini D; Bocci G; Del Tacca M
Drug Metab Dispos; 1995 Jul; 23(7):713-7. PubMed ID: 7587959
[TBL] [Abstract][Full Text] [Related]
7. Dosing sequence-dependent pharmacokinetic interaction of oxaliplatin with paclitaxel in the rat.
Liu J; Kraut EH; Balcerzak S; Grever M; D'Ambrosio S; Chan KK
Cancer Chemother Pharmacol; 2002 Dec; 50(6):445-53. PubMed ID: 12451470
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics of carbon nanoparticle-paclitaxel suspension for use in intraperitoneal chemotherapy.
Cai Y; Zhang X
Hepatogastroenterology; 2013; 60(128):1998-2003. PubMed ID: 24719940
[TBL] [Abstract][Full Text] [Related]
9. [A case of advanced gastric cancer treated with weekly paclitaxel with measurement of paclitaxel concentrations in blood and ascites].
Kojima T; Matsui T; Uemura T; Fujimitsu Y; Kato J; Kojima H
Gan To Kagaku Ryoho; 2003 Oct; 30(10):1529-31. PubMed ID: 14584291
[TBL] [Abstract][Full Text] [Related]
10. Translymphatic chemotherapy by intrapleural placement of gelatin sponge containing biodegradable Paclitaxel colloids controls lymphatic metastasis in lung cancer.
Liu J; Meisner D; Kwong E; Wu XY; Johnston MR
Cancer Res; 2009 Feb; 69(3):1174-81. PubMed ID: 19176391
[TBL] [Abstract][Full Text] [Related]
11. Cytoreductive surgery and intraoperative hyperthermic intraperitoneal chemotherapy with paclitaxel: a clinical and pharmacokinetic study.
de Bree E; Rosing H; Filis D; Romanos J; Melisssourgaki M; Daskalakis M; Pilatou M; Sanidas E; Taflampas P; Kalbakis K; Beijnen JH; Tsiftsis DD
Ann Surg Oncol; 2008 Apr; 15(4):1183-92. PubMed ID: 18239973
[TBL] [Abstract][Full Text] [Related]
12. Enhanced absorption and tissue distribution of paclitaxel following oral administration of DHP 107, a novel mucoadhesive lipid dosage form.
Shin BS; Kim HJ; Hong SH; Lee JB; Hwang SW; Lee MH; Yoo SD
Cancer Chemother Pharmacol; 2009 Jun; 64(1):87-94. PubMed ID: 18941747
[TBL] [Abstract][Full Text] [Related]
13. Multi-targeted antifolate (MTA): pharmacokinetics of intraperitoneal administration in a rat model.
Pestieau SR; Stuart OA; Sugarbaker PH
Eur J Surg Oncol; 2000 Nov; 26(7):696-700. PubMed ID: 11078617
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics and neutrophil toxicity of paclitaxel orally administered in mice with recombinant interleukin-2.
Jamois C; Comets E; Mentré F; Marion S; Farinotti R; Bonhomme-Faivre L
Cancer Chemother Pharmacol; 2005 Jan; 55(1):61-71. PubMed ID: 15378273
[TBL] [Abstract][Full Text] [Related]
15. Association of Paclitaxel pharmacokinetics with the development of peripheral neuropathy in patients with advanced cancer.
Mielke S; Sparreboom A; Steinberg SM; Gelderblom H; Unger C; Behringer D; Mross K
Clin Cancer Res; 2005 Jul; 11(13):4843-50. PubMed ID: 16000582
[TBL] [Abstract][Full Text] [Related]
16. Mechanistic population pharmacokinetics of total and unbound paclitaxel for a new nanodroplet formulation versus Taxol in cancer patients.
Bulitta JB; Zhao P; Arnold RD; Kessler DR; Daifuku R; Pratt J; Luciano G; Hanauske AR; Gelderblom H; Awada A; Jusko WJ
Cancer Chemother Pharmacol; 2009 May; 63(6):1049-63. PubMed ID: 18791718
[TBL] [Abstract][Full Text] [Related]
17. Altered pharmacokinetics of paclitaxel by the concomitant use of morin in rats.
Choi BC; Choi JS; Han HK
Int J Pharm; 2006 Oct; 323(1-2):81-5. PubMed ID: 16806758
[TBL] [Abstract][Full Text] [Related]
18. Intravenous administration of paclitaxel in Sprague-Dawley rats: what is a safe dose?
Shord SS; Camp JR
Biopharm Drug Dispos; 2006 May; 27(4):191-6. PubMed ID: 16566060
[TBL] [Abstract][Full Text] [Related]
19. [Pharmacokinetics of paclitaxel in experimental animals. Part 1. Blood level].
Fujita H; Okamoto M; Takao A; Mase H; Kojima H
Gan To Kagaku Ryoho; 1994 Apr; 21(5):653-8. PubMed ID: 7908791
[TBL] [Abstract][Full Text] [Related]
20. Influence of Cremophor El on the bioavailability of intraperitoneal paclitaxel.
Gelderblom H; Verweij J; van Zomeren DM; Buijs D; Ouwens L; Nooter K; Stoter G; Sparreboom A
Clin Cancer Res; 2002 Apr; 8(4):1237-41. PubMed ID: 11948138
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
